Related Experiment Video
Updated: May 5, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy
Nadav Willner1, Shimon Storch, Tamar Tadmor
1Department of Internal Medicine B, Bnai-Zion Hospital, Haifa, Israel, nadav.willner@gmail.com.
Background:
Methotrexate (MTX), an antimetabolite of folic acid, is the drug of choice for the nonsurgical management of ectopic pregnancy. MTX-related toxicity may include leukopenia, thrombocytopenia, pancytopenia, nausea, vomiting, stomatitis, mucositis, and liver and lung toxicity, depending primarily on the dosage of the drug and patients' renal function. Currently, the use of MTX in hemodialysis patients, even at a low dosage, is controversial, and no clear-cut guidelines are available.
Case Report:
We report here a rare case of a life-threatening complication characterized by severe pancytopenia and skin and mucosal injury, which developed in a young patient on hemodialysis after oral treatment with MTX for ectopic pregnancy.
Conclusion:
We conclude that even low-dose MTX administration is not to be used in patients with renal insufficiency, and when no other therapeutic options are available we suggest taking several clinical measures to prevent or treat myelosuppression.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Therapeutic Drug Monitoring: Affecting Factors
Hemodialysis II: Procedure and Complications
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Risk factors
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy